Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T22:19:48.699Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of piracetam on the dexamethasone suppression test in Alzheimer's and multi-infarct dementias

Published online by Cambridge University Press:  16 April 2020

G Charles ,
MJ Panzer ,
R Machowski ,
A Lefevre  and
J Mirel
G Charles
Affiliation:
Service de Psychiatrie, Centre Hospitalier Universitaire Vesale, 706 route de Gozée, B 6110Montigniy-le-Tilleul, Belgium
MJ Panzer
Affiliation:
Department of Psychiatry, University of Michigan, Ann Arbor, Ml 48109, USA
R Machowski
Affiliation:
Hôpital Vincent Van Gogh, B 6030, Marchienne-au-Pont, Belgium
A Lefevre
Affiliation:
Service de Psychiatrie, Centre Hospitalier Universitaire Vesale, 706 route de Gozée, B 6110Montigniy-le-Tilleul, Belgium
J Mirel
Affiliation:
Service de Psychiatrie, Centre Hospitalier Universitaire Vesale, 706 route de Gozée, B 6110Montigniy-le-Tilleul, Belgium
Get access

Summary

Results of the dexamethasone suppression test (DST) in demented nondepressed patients have varied considerably, and there is evidence that these depend on the type of dementia, ie, Alzheimer’s disease (AD) or multi-infarct dementia (MID). AD is characterized by decreased central acetylcholine (Ach) activity, while MID is thought to be vascular in etiology. Pirecetam normalizes cerebral blood flow, along with other positive hemorheological properties. It may also increase central Ach levels. We performed the DST twice, 1 week apart, on 96 stable, demented geriatric inpatients. In 33 (21 AD, 11 MID), piracetam was started at an oral dose of 4.8 g/d 4-6 months before the first DST. The remaining 64 (39 AD, 25 MID) were untreated. Among untreated patients, those with MID were less suppressible (P < 0.001 and P= 0.01) and had more week-to-week variability (P = 0.0006) in the DST than AD patients. This is consistent with our previous findings. However, treated patients showed no difference in either postdexamethasone cortisol levels or reproducibility of DST results. We interpret these findings to mean that piracetam, by increasing central Ach, makes AD patients less suppressible on the DST, and by maintaining more constant limbic blood flow, makes MID patients more DST stable.

Keywords

acetylcholineAlzheimer’s diseasedementiadexamethasone suppression testmodified ischemic scoremulti-infarct dementiapiracetamSandoz Clinical Assessment Geriatric Scale
Type
Original article
Information
European Psychiatry , Volume 6 , Issue 4 , 1991 , pp. 195 - 200
Copyright
Copyright © Elsevier, Paris 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barnhardt, MI (1981) Plaquettes hyperréactives et maladie thromboembolique Essentialia 18/2, 12–16Google Scholar
Balldin, JGottfries, CGKarlsson, ILinstedt, GLangstrom, GWalinder, J (1983) DST and serum prolactin in dementia disorders Br J Psychiatry 143, 277CrossRefGoogle ScholarPubMed
Bartus, GA (1981) Profound effect of combining choline and piracetam in memory enhancement and cholinergic functions in aged rats Neurobiol Aging 2, 105–111CrossRefGoogle Scholar
Carnes, MSmith, JCKalin, NHBauwens, SF (1983) The DST in demented outpatients with and without depression Psychiatry Res 9, 337CrossRefGoogle ScholarPubMed
Carroll, BJGreden, JFhaskett, RFeinberg, MAlbala, AAMartin, FIRRubin, RTHeath, BSharp, PTMcLeod, WLMcLeod, LF (1980) Neurotransmitter studies of neuroendrocrine pathology in depression. Acta Psychiatr Scand (suppl) 280, 183CrossRefGoogle Scholar
Castro, PLemaire, MToscano-Aquilar, MHerchuelz, A (1983) Depression dementia and DST (letter) Am J Psychiatry 140, 1386Google Scholar
Charles, GVandewalle, JMeunier, JCWilmotte, JNoel, GFossoul, CMardens, YMendlewicz, J (1981) Plasma and urinary Cortisol levels after dexamethasone in affective disorders J Affective Disord 3, 397CrossRefGoogle ScholarPubMed
Charles, GRush, AJOrsulak, PJ (1985) Arecoline reverses dexamethasone suppression. Communication, 40th Meeting, Soc Biol Psychiatry, Dallas, May 16–19Google Scholar
Charles, GLefevre, AMirel, JRush, J (1986) Suppression of Cortisol following dexamethasone in demented patients Psychiatry Res 17, 173–182CrossRefGoogle ScholarPubMed
Clauss, RMBabu, STung, DYRedisch, W (1981) Automated physiological profile assessment of effects of altered cardiovascular dynamics on brain blood flowIn: Diagnosis and Treatment of Brain Ischemia (Carney, ALAnderson, EM, eds) Raven Press, NYGoogle Scholar
Ferrier, INPascual, JCharlton, BGWright, CLeare, AGriffiths, HWFairbairn, AFEdwardson, JA (1988) Cortisol, ACTH and dexamethasone concentrations in a psychogeriatric population Biol Psychiatry, 23, 252–260Google Scholar
Giurgea, CMouravieff-Lesuisse, F (1972) Effet facilitateur du piracetam sur un apprentissage répétitif chez le rat J Pharmacol 3/1, 17–30Google Scholar
Hachinski, VCIliff, LDZilkha, EDuboulay, GMcAllister, VLMarshall, JRussel, RWRSymon, L (1975) Cerebral blood flow and dementia Arch Neurol 32, 632CrossRefGoogle ScholarPubMed
Henry, RLNalbandian, RM (1979) Platelet suppression by piracetam. 1st Int Symp, Nootropic Drugs, Rio de Janeiro, BrazilGoogle Scholar
Herrschaft, H (1978) Die Wirkung von Piracetam auf die Gehirndurchblutung des Menschen. Quantitative regionale Hirndurchblutungsmessungen bei der akuten zerzbraten ischämie Med Klin 73/6, 195–202Google Scholar
Katzman, R (1986) Alzheimer’s disease N Engl J Med 314, 964–973CrossRefGoogle ScholarPubMed
Khachaturian, ZS (1985) Diagnosis of Alzheimer’s disease Arch Neurol 42, 1097–1105CrossRefGoogle ScholarPubMed
Kittner, STWhite, LRFarmer, MEWolz, MKaplan, EMoes, EBrody, JAFeinleib, M (1986) Methodological issues in screening for dementia J Chron Dis 39 (N°3), 163–170CrossRefGoogle ScholarPubMed
Kordon, CEnjalbert, AHery, MJoseph-Bravo, PIRotsztejn, WRuberg, M (1981) Role of neurotransmitters in the control of adrenohypophyseal secretionIn: Handbook of the Hypothalamus. Vol II (Morgane P, JPandsepp, J, eds) Marcel Dekker, NYGoogle Scholar
Loew, DSchuster, OGraul, EH (1986) Dose-dependent pharmacokinetics of dexamethasone Eur J Clin Pharmacol 30, 225–230CrossRefGoogle ScholarPubMed
Mahendra, B (1984) Dementia and abnormal DST (letter) Br J Psychiatry 143, 98CrossRefGoogle Scholar
Mendlewicz, JCharles, GFranckson, JM (1982) The dexamethasone suppression test in affective disorders: relationship to clinical and genetic subgroups Br J Psychiatry 141, 464CrossRefGoogle ScholarPubMed
Pilch, HMuller, WE (1988) Piracetam elevates mucorinic cholinergic receptor density in the frontal cortex of aged but not of young mice Psychopharmacology 94, 74CrossRefGoogle Scholar
Raskind, MPeskind, ERivard, HFVeith, RBarnes, R (1982) Dexamethasone suppression test and corticol circadian rhythm in primary degenerative dementia Am J Psychiatry 139, 1468Google Scholar
Rosen, WGTerry, RDFuld, PAKatzman, RPeck, A (1980) A pathological verification of ischemic score in differentiation of dementias Ann Neurol 7, 486CrossRefGoogle ScholarPubMed
Spar, JEGerner, R (1982) Does DST distinguish dementia from depression? Am J Psychiatry 139, 238Google Scholar
Targino de Aranjo J (1979) The action of piracetam and acetamide as sickling inhibitors and desickling agents on erythrocytes of patients with sickle cell disease. 1st Int Symp Nootropic Drugs, Rio de Janeiro, Brazil, 257–264Google Scholar
Venn, RD (1983) The Sandoz Clinical Assessment Geriatric (SCAG) Scale: a general purpose psychogeriatric rating scale Gerontology 29, 185CrossRefGoogle ScholarPubMed
World Health Organization (1978) Mental Disorders: Glossary and Guide to Their Classification in Accordance with the 9th Revision of the International Classification of Diseases. WHO, GenevaGoogle Scholar
Wurtman, AH (1981) Piracetam diminishes hippocampal acetylcholine levels in rats Life Sci 24, 1091–1093CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.